became available as a unique option for oral MS treatment in our hospital in 2017.

Aim and objectives To describe our experience with the use of TRF and assess its safety profile, as disease modifying therapies (DMTs) work differently and have different adverse reactions (AR).

Material and methods An observational retrospective study was conducted from January 2017 to January 2020. Collected variables from medical records were: age, sex, expanded disability status scale score (EDSS), previous DMTs, safety profile (AR, suspension of TRF treatment) and results of blood tests. Sustained disability progression was defined as at least a 1 point increase from the baseline EDSS score ≤ 5.5 (or at least a 0.5 point increase for those with a baseline EDSS score > 5.5) sustained for at least 12 weeks.¹

Results 45 patients were analysed, 10 men and 35 women (mean age 35.7 years). TRF was the firstline drug for 10 patients, the rest had switched to TRF from parenteral therapies: 7 subcutaneous glatiramer acetate, 20 intramuscular or subcutaneous interferon beta and 2 intravenous natalizumab. The main reasons for change were: convenience of oral administration, poor tolerance and AR at the site of injection. The average duration for TRF was 2.5 years with no suspension recorded. In this period, for 30 patients EDSS score remained stable. The mean change in EDSS from baseline was 0.7; no increase in disability progression. 30 patients showed no AR and 15 patients presented gastrointestinal disorders (9), temporary alopecia (4) or headache (2). 9 patients experienced moderate elevation of liver enzymes.

Conclusion and relevance TRF seemed to have a manageable safety profile, was well tolerated, and no new or unexpected AR were reported and there were no suspensions of treatment. Because our experience reflects only 3 years, increased monitoring is necessary to assess the long term safety.

REFERENCES AND/OR ACKNOWLEDGEMENTS

1. AUBAGIO (package insert). Cambridge, MA: Genzyme Corporation

Conflict of interest No conflict of interest

4CPS-309 BARRIERS TO ADHERENCE WITH PRESCRIBED TREATMENTS IN MULTIPLE SCLEROSIS PATIENTS

¹SM Oprea*, ²S Negres. ¹University Emergency Hospital Bucharest, Pharmacy, Bucharest, Romania; ²University of Medicine and Pharmacy Carol Davila, Pharmacology and Clinical Pharmacy Department, Bucharest, Romania

10.1136/ehpharm-2021-eahpconf.141

Background and importance Multiple sclerosis (MS) is a chronic progressive disease, one of the main causes of invalidity among young adults. Adherence may be difficult because treatment benefits are not immediately apparent, and most disease modifying therapies (DMTs) have tolerability and safety issues.

Aim and objectives In our hospital, where almost 800 MS patients are treated monthly, no study has assessed adherence, so the purpose of this study was to evaluate adherence and identify patient reported barriers regarding adherence.

Material and methods An observational retrospective study was conducted (January 2017 to January 2019). We evaluated adherence using missed dose ratio (MDR), and identified and quantified barriers to adherence using the MS treatment adherence questionnaire (MSTAQ). This tool has 30 items in

Abstract 4CPS-309 Table 1

MS-TAQ subscale	No of items	Score		
		Mean	Range	Observations
DMT barriers	13	2.18 ¹	0-39	63% of patients reported no barriers (score 0)
DMT side effects	10	9.30 ²	0-40	Only 11.6% reported no SE (score 0)
DMT coping strategies	7	1.22 ³	0-7	36.6% do not use coping strategies

¹Most common barriers, for 22 patients, were forgetting to administer DMT (58%), not "in the mood" to take DMT (22%) and feeling tired of taking DMT (16%).

²88.4% of patients reported SE such as injection phobia, injection site reaction and tolerability concerns.

³15 patients reported SE but no coping strategies in place, maybe because they were not aware of them.

three subscales: DMT barriers to adherence, DMT side effects (SE) and DMT coping strategies. We also collected demographic (age, sex) and treatment information (current DMT, DMT history, reason for switch therapy and exposure to treatment).

Results 60 patients (44 women), average age 40.47 years had a mean treatment exposure of 6.38 years. Adherence was high because only 11 had missed one or more doses in the last month (MDR > 0). When asked about missed dose in general, 22 patients reported barriers to taking medication. DMT scores are described in table 1.

Conclusion and relevance Overall, adherence was high even though there were some barriers to adherence. SE and long duration of treatment could affect adherence, which is why it is important to detect and overcome barriers using such questionnaires, to identify in time non-adherent patients and counsel them appropriately on how to use more coping strategies.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Conflict of interest No conflict of interest

4CPS-310 TOFACITINIB EFFECTIVENESS AND SAFETY RESULTS: REAL WORLD DATA

R Álvarez Sánchez, C Castaño-Amores*, P Nieto Gómez, A Rodríguez Delgado, S Portillo Haro, P Moreno Rodríguez, J Cabeza Barrera. Farmacia Hospital San Cecilio, Pharmacy, Granada, Spain

10.1136/ehpharm-2021-eahpconf.142

Background and importance Tofacitinib is an oral JAK inhibitor indicated for the treatment of rheumatoid arthritis, psoriasis arthritis and ulcerative colitis. The efficacy and safety of tofacitinib have been shown in several randomised clinical trials.

Aim and objectives To evaluate the effectiveness and safety of tofacitinib in all indications used in a real world cohort of patients in a third level hospital.

Material and methods This was a retrospective observational study of patients who received tofacitinib from 2017 to March 2020. Demographic, clinical characteristics at baseline and outcomes analysed were: age, sex, diagnosis, number of days treated with tofacitinib, previous lines of treatment, objective response and adverse effects.

Results 30 patients were treated with tofacitinib from 2017 to March 2020, 23 women and 7 men, with a median age of 55 (48–62) years; 40% of patients were overweight. 23 patients were diagnosed with rheumatoid arthritis, 3 patients with psoriasis arthritis, 1 patient with vitiligo, 1 patient with alopecia areata and 1 patient with polyarthritis. 50% of patients were pre-exposed to at least one biological agent and all of the patients were pre-exposed to methotrexate, leflunomide and/or hydroxychloroquine. Median time to stop tofacitinib was 307 (114–557) days. Reasons for stopping tofacitinib were: insufficient response (n=9), infection (n=1), headache (n=3), haematemesis (n=1) and pregnancy (n=1). 15 patients have continued treatment with tofacitinib with a good response. Elevation of liver enzymes, or changes in the levels of lymphocytes, neutrophils and haemoglobin have not been detected in any patient. 30% of patients had adverse events; more frequent adverse events were infections in 13% of patients and headache in 13% of patients.

Conclusion and relevance The efficacy and safety of tofacitinib have been demonstrated in clinical trials. This retrospective analysis of real life data showed that tofacitinib was also effective and safe in a real life setting but only 50% of the patient cohort achieved a response with a dose of tofacitinib 5 mg twice daily. Due to the size of the group, these results should be interpreted with caution; future analysis in clinical practice is necessary.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Conflict of interest No conflict of interest

4CPS-311 REAL WORLD TOXICITY AND MANAGEMENT OF CHIMERIC ANTIGEN RECEPTOR T CELL THERAPIES TARGETING CD19 IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES

R Jiménez-Galán, P Ciudad-Gutiérrez, E Prado-Mel*. *Virgen Del Rocío Hospital, Pharmacy Service, Seville, Spain*

10.1136/ejhp-pharm-2021-eahpconf.143

Background and importance Chimeric antigen receptor-T (CAR-T) has demonstrated clinical efficacy in haematologic malignancies but it also has a relevant toxic side effect profile.

Aim and objectives To describe the toxicity and management of CAR-T cell therapies (CARTs) (tisagenlecleucel (Tisa-cel) and axicabtagene ciloleucel (Axi-cel)) in a real world population with haematological malignancies.

Material and methods A retrospective study was conducted in all patients treated with CARTs in our hospital (August 2019 to September 2020). Data collected included age, gender, diagnosis, hospital stay, admission to the intensive care unit (ICU), length of ICU stay and the main adverse events (AE) detected (cytokine release syndrome (CRS), neurological toxicity, hypogammaglobulinaemia, febrile neutropenia and infections) and need for tocilizumab and/or corticosteroids to treat AE. Statistical analysis was performed using SPSS V.21.0.

Results 32 patients were included (53.1% men). Axi-cel was administered to 53.1% of patients, of whom 70.6% had diffuse large B-cell lymphoma (DLBCL) and the remaining had primary mediastinal large B-cell lymphoma (PMBCL). The rest were treated with Tisa-cel; 60.0% had DLBCL and the others had B-cell precursor acute lymphoblastic leukaemia (ALL). Median age in the ALL population was 9 years (6–14) and

mean age in patients with DLBCL and PMBCL was 57.7 years ($\pm$ 8.8). Median hospital stay was 15 days (13–21). Two patients died during admission and one remained admitted at the data cut-off date. 15.6% required admission to the ICU and mean stay was 7 days ($\pm$ 6.1). Two patients presented with mild hypersensitivity reaction during CAR-T cell infusion. 81.3% presented CRS and neurological toxicity occurred in 37.5%. During admission, 78.1% presented with febrile neutropenia and 15.6% had active infections. Hypogammaglobulinaemia was observed in three patients. Tocilizumab and corticosteroids were administered in 21.9% of patients in both cases. CRS and febrile neutropenia rates were similar in patients treated with Tisa-cel and Axi-cel (73.7% vs 88.2% and 80.0% vs 76.5%, respectively). Neurological toxicity was more frequent with Axi-cel (52.9% vs 20%).

Conclusion and relevance CAR-T cell therapy was generally well tolerated with a low rate of severe or life threatening AE. CRS was the most frequent AE and no differences were found between Axi-cel and Tisa-cel. Neurological toxicity rates were similar to those observed in clinical trials with Tisa-cel and lower than with Axi-cel. The need for tocilizumab and/or corticosteroids in Axi-cel patients was lower than in clinical trials.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Conflict of interest No conflict of interest

4CPS-312 PHARMACEUTICAL INTERVENTIONS IN A NON-ONCOHAEMATOLOGICAL DAILY HOSPITAL

JA Domínguez Menéndez*, A Revuelta Amallo, C Vila Gallego, M Vara Urruchua, U Blázquez Urtizberea, S Vallinas Hidalgo, E Oñate Muzas, E Tamayo Orbegozo, A Aguirrezabal Arredondo. *Basurto Hospital, Pharmacy, Bilbao, Spain*

10.1136/ejhp-pharm-2021-eahpconf.144

Background and importance The role of the pharmacist in the validation and dispensing of medications is already known. But the increasingly frequent use of high cost drugs makes that role essential for the sustainability of health systems.

Aim and objectives To describe and analyse the pharmaceutical interventions carried out in a non-oncohaematological daily hospital (NOHDH) and to evaluate the economic impact of these interventions.

Material and methods From April 2019 to March 2020, pharmacist interventions in the validation and dispensing of electronic prescriptions of intravenous treatments in the NOHDH were recorded. It should be noted that preparation of infusions is not centralised in the pharmacy but is carried out in the daily hospital units. Infusions prepared in the pharmacy, acute treatments and intravenous iron were excluded. To calculate the economic impact, only the dose administered and the average cost of drugs during the year of the study were considered.

Results 30 interventions were carried out in 434 patients (6.9% patients) and 2240 dispensations (1.3% dispensations). 29 were accepted (97%). They were classified according to the type of intervention: 15 presentation changes (14 to a biosimilar), 10 dose adjustments (5 to commercial presentations), 4 request errors (1 of dose and 3 of administration date) and 1 change of medication. Intervention according to services: 10 rheumatology (9.6% of patients and 2.2% of dispensations), 5 nephrology (26.3% and 11.4%), 4 digestive